Trastuzumab resistance
Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer
... develop resistance to trastuzumab through mechanisms still poorly ...in trastuzumab-resistance, as is overexpression of the scaffold protein ...acquired resistance to trastuzumab ...
16
LncRNA-ATB promotes trastuzumab resistance and invasion- metastasis cascade in breast cancer
... Trastuzumab resistance is leading cause of mortality in HER2-positive breast cancers, and the role of TGF-β-induced epithelial-mesenchymal transition (EMT) in trastuzumab resistance is well ...
12
Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer
... we have taken an unbiased genome-wide approach to identify genes and pathways that may drive and/or contribute to TzR. By utilizing next generation RNA-seq (RNA-seq) of RNA isolated from tumors and cell lines that are ...
15
Novel strategies for HER 2 positive metastatic disease: mechanisms and therapeutic options to overcome trastuzumab resistance
... adjuvant trastuzumab might be refractory (primary resistance) or might become resistant (secondary resistance) to ...secondary trastuzumab resistance are not yet fully ...in ...
24
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer
... with trastuzumab resistance [21], we sought to investigate whether there was any rela- tionship at the protein level between pSTAT3, PTEN, and other proteins regulated by STAT3 in our clinical ...
10
Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer
... However, trastuzumab resistance emerged as a major problem in its clinical ...underlying trastuzumab resistance, we performed RNA-Seq to analyze the gene expression variation in ...
9
A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway
... while trastuzumab resistance was enhanced. Whereas, resistance to trastuzumab was attenuated in MACC1- downregulated groups, simultaneously, the phosphoryl- ation of AKT decreased and the ...
15
<p>Mechanism of trastuzumab resistance caused by HER-2 mutation in breast carcinomas</p>
... of resistance caused by the ...Her-2-related resistance using the MCF7 cell line which is a commonly used breast cancer cell line that has been promoted for >40 years by multiple research groups and has ...
12
An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
... of trastuzumab to inhibit the in vitro cell proliferation correlates with ErbB3/ PI3K/AKT pathway inhibition ...in trastuzumab-sensitive BT-474 cells, trastuzumab efficiently suppressed the cell ...
13
HER2 therapy: Molecular mechanisms of trastuzumab resistance
... to trastuzumab, our group launched a clinical trial of trastuzumab in combination with the mTOR inhibitor RAD001 in patients with HER2-overexpressing MBC resistant to trastuzumab-based ...
8
Relationship between <em>HER2</em> gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment
... for trastuzumab resistance (PTEN, IGF-1R, MUC4, EGFR, HER3, HER4, and mutation status of PIK3CA) as well as their influence on survival of HER2-positive breast cancer patients treated with adjuvant ...
11
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
... of trastuzumab-resistant xenografted tumors, through a collaborative anti-tumor and anti-angiogenic effect For in vivo experiments, we grafted each mouse (n = 10) with two BT474-R tumors, one on each ...their ...
13
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
... The BOLERO-3 study compared the combination of everolimus, trastuzumab plus vinorelbine to trastuzumab and vinorelbine. The association of the mTOR inhibitor with vinorelbine significantly improved PFS ...
10
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
... 11]. Trastuzumab is thought to exert its anti-tumor activity partly by accelerating the internalization and degradation of HER2 and thus blocking downstream ...to trastuzumab and the majority who initially ...
14
Vasculogenic mimicry is associated with trastuzumab resistance of HER2 positive breast cancer
... Tzm resistance in HER2-positive breast cancer cells in vitro and in the clinical ...Tzm resistance and the vascular phenotype, long-term HER2 blockade by Tzm leads to the activation of alter- native ...
18
Adipose cells promote resistance of breast cancer cells to trastuzumab mediated antibody dependent cellular cytotoxicity
... of resistance to trastuzumab have been ...to trastuzumab activity, has been shown to confer trastuzumab resistance both in vitro and in vivo ...to trastuzumab-based therapy than ...
14
Prediction of key genes and pathways involved in trastuzumab resistant gastric cancer
... cancer, trastuzumab remains one of the inten- sively studied ...of trastuzumab resistance and the prognostic values of hub genes and opened the way for fu- ture research in combination therapy in ...
12
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
... caused resistance of HER2-positive breast and gastric cancer cells to lapatinib and ...induces resistance to these agents [16, ...exhibited resistance to these agents in vitro and in vivo, although ...
12
Protein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2
... Background: Trastuzumab resistance in HER-2 positive breast cancer cells is closely related to overexpression of both epidermal growth factor receptor (EGFR) and human epidermal recep- tor ...of ...
11
Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer
... mab resistance, different functional studies were carried ...to trastuzumab resistance such as β1 or α6β4 [49, ...in trastuzumab response ...in trastuzumab treatment re- ...in ...
16